DOCSLIB.ORG

Hemebiotech Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hemebiotech Template University of Texas Medical Branch Porphyria Laboratory and Center Protocol: Panhematin™ Prevention Study Date: June 18, 2019 Version: 7 IND 13,929 Clinical Study Protocol Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria Trial phase: II This document is confidential and was prepared by and is the property of The University of Texas Medical Branch. Access to and reproduction of this document by permission only. Page 1 University of Texas Medical Branch Porphyria Laboratory and Center Protocol: Panhematin™ Prevention Study Date: June 18, 2019 Version: 7 IND 13,929 Table of Contents 1. Introduction ....................................................................................................... 5 1.1 Description of acute porphyrias and current treatment ................................. 5 1.2 Description of the drug under study ............................................................... 12 1.3 Rationale for this clinical trial .......................................................................... 13 2. Objectives ........................................................................................................ 14 2.1 Endpoints. .......................................................................................................... 15 3. Trial Design ...................................................................................................... 15 3.1 Type of Trial ....................................................................................................... 15 3.2 Rationale for the trial design ............................................................................ 17 3.3 Treatment of Subjects and Rationale for Treatment ..................................... 17 4. Trial Population ............................................................................................... 18 4.1 Number of patient and sites ............................................................................. 18 4.2 Recruitment of Subjects ................................................................................... 19 4.3 Inclusion Criteria ............................................................................................... 19 4.4 Exclusion Criteria .............................................................................................. 22 4.5 Withdrawal Criteria ............................................................................................ 22 4.6 Subject Replacement ........................................................................................ 23 5. Study materials ............................................................................................... 23 5.1 Study drug reconstitution and administration............................................... 23 5.2 Placebo preparation and administration ........................................................ 25 5.3 Timing of administration of Panhematin™ or placebo ................................. 26 5.4 Glucose administration .................................................................................... 26 5.5 Blinding .............................................................................................................. 26 5.6 Treatment of acute attacks during the study ................................................. 27 5.7 Randomization ................................................................................................... 27 This document is confidential and was prepared by and is the property of The University of Texas Medical Branch. Access to and reproduction of this document by permission only. Page 2 University of Texas Medical Branch Porphyria Laboratory and Center Protocol: Panhematin™ Prevention Study Date: June 18, 2019 Version: 7 IND 13,929 6. Methods and Assessments ........................................................................... 28 6.1 Visit Procedures ................................................................................................ 28 6.1.1 Visit 1 – Screening and Enrollment .................................................................................... 28 6.1.2 Visit 2: ..................................................................................................................................... 29 6.1.3 Visit 3, 4, etc. ......................................................................................................................... 30 6.2 Assessments for Efficacy................................................................................. 30 6.2.1 Clinical improvement ............................................................................................................ 30 6.2.2 Biochemical measures of improvement ............................................................................. 30 6.3 Safety Assessment............................................................................................ 30 6.3.1 Symptoms .............................................................................................................................. 30 6.3.2 Physical Examination ........................................................................................................... 30 6.3.3 Blood counts and chemistries ............................................................................................. 31 6.3.4 Urinalysis ................................................................................................................................ 31 6.3.5 Pregnancy test ...................................................................................................................... 31 6.3.6 Adverse Events ..................................................................................................................... 31 7. Adverse Events ............................................................................................... 31 7.1 Definitions (ICH) ................................................................................................ 31 8. Case Report Forms ......................................................................................... 32 8.1 Rules for Completing CRFs ............................................................................. 32 8.2 Corrections to CRFs.......................................................................................... 33 8.3 CRF Review and Data Entry ............................................................................. 33 9. Monitoring Procedures .................................................................................. 33 10. Data Management ....................................................................................... 34 11. Evaluability of Subjects for Analysis ....................................................... 35 12. Statistical Analyses .................................................................................... 35 12.1 Purposes ............................................................................................................ 35 12.2 Variables for statistical analyses .................................................................... 35 12.2.1 Efficacy variables ............................................................................................................. 35 12.2.2 Safety variables ................................................................................................................ 36 12.3 Statistical Methods ............................................................................................ 36 This document is confidential and was prepared by and is the property of The University of Texas Medical Branch. Access to and reproduction of this document by permission only. Page 3 University of Texas Medical Branch Porphyria Laboratory and Center Protocol: Panhematin™ Prevention Study Date: June 18, 2019 Version: 7 IND 13,929 12.4 Sample size determination ............................................................................... 36 12.5 Interim analyses ................................................................................................ 37 13. Ethical considerations ................................................................................ 37 13.1 Assessment of Risks ........................................................................................ 37 13.2 Assessment of benefits .................................................................................... 40 13.3 Research consent .............................................................................................. 40 13.4 Institutional Review Boards ............................................................................. 40 13.5 Regulatory Authorities ...................................................................................... 41 14. Premature Termination of the Trial ........................................................... 41 15. Deviations from the Protocol..................................................................... 41 16. Essential Documents .................................................................................. 41 17. Reports and Publication ............................................................................. 42 18. Retention of Clinical Trial Documents ..................................................... 42 19. Indemnity Statement ................................................................................... 42 20. Quality Control and Quality Assurance ................................................... 42 21. References cited.........................................................................................
Load more

Recommended publications
  • Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
    Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact PI: Dr. Manisha Balwani NCT01688895 Document Date: Jun 26, 2015 RDCRN PC #7207 EPP Natural History Version Date: V2 26Jun2015 Rare Diseases Clinical Research Network Porphyrias Consortium Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact This protocol is for research purposes only and should not be copied, redistributed, or used for any other purpose. The procedures in this protocol are intended only for use by the Porphyrias Consortium investigators in carefully controlled settings. The Study Chair of this study should be consulted before using this protocol. Study Chair: Manisha Balwani, MD, MS Department of Genetics & Genomic Sciences Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place, Box 1497 New York, NY 10029 Phone: 212-241-0915 Fax: 212-426-9065 Email: [email protected] Page 1 of 31 RDCRN PC #7207 EPP Natural History Version Date: V2 26Jun2015 Table of Contents Contents Participating Institutions/Investigators Table (contact information)............................................................... 4 1. Synopsis .................................................................................................................................................... 6 1.A. Protocol Overview .............................................................................................................................. 8 2. Objective
    [Show full text]
  • Noncanonical Coproporphyrin-Dependent Bacterial Heme Biosynthesis Pathway That Does Not Use Protoporphyrin
    Noncanonical coproporphyrin-dependent bacterial heme biosynthesis pathway that does not use protoporphyrin Harry A. Daileya,b,c,1, Svetlana Gerdesd, Tamara A. Daileya,b,c, Joseph S. Burcha, and John D. Phillipse aBiomedical and Health Sciences Institute and Departments of bMicrobiology and cBiochemistry and Molecular Biology, University of Georgia, Athens, GA 30602; dMathematics and Computer Science Division, Argonne National Laboratory, Argonne, IL 60439; and eDivision of Hematology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132 Edited by J. Clark Lagarias, University of California, Davis, CA, and approved January 12, 2015 (received for review August 25, 2014) It has been generally accepted that biosynthesis of protoheme of a “primitive” pathway in Desulfovibrio vulgaris (13). This path- (heme) uses a common set of core metabolic intermediates that way, named the “alternative heme biosynthesis” path (or ahb), has includes protoporphyrin. Herein, we show that the Actinobacteria now been characterized by Warren and coworkers (15) in sulfate- and Firmicutes (high-GC and low-GC Gram-positive bacteria) are reducing bacteria. In the ahb pathway, siroheme, synthesized unable to synthesize protoporphyrin. Instead, they oxidize copro- from uroporphyrinogen III, can be further metabolized by suc- porphyrinogen to coproporphyrin, insert ferrous iron to make Fe- cessive demethylation and decarboxylation to yield protoheme (14, coproporphyrin (coproheme), and then decarboxylate coproheme 15) (Fig. 1 and Fig. S1). A similar pathway exists for protoheme- to generate protoheme. This pathway is specified by three genes containing archaea (15, 16). named hemY, hemH, and hemQ. The analysis of 982 representa- Current gene annotations suggest that all enzymes for pro- tive prokaryotic genomes is consistent with this pathway being karyotic heme synthetic pathways are now identified.
    [Show full text]
  • Mapping Mass Spectral Databases in Genome-Scale Metabolic Networks Reveals Poorly Covered Areas
    H OH metabolites OH Article Mind the Gap: Mapping Mass Spectral Databases in Genome-Scale Metabolic Networks Reveals Poorly Covered Areas Clément Frainay 1 , Emma L. Schymanski 2,3, Steffen Neumann 4,5 , Benjamin Merlet 1, Reza M. Salek 6 , Fabien Jourdan 1,* and Oscar Yanes 7,8,* 1 Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, 31555 Toulouse, France; [email protected] (C.F.); [email protected] (B.M.) 2 Eawag: Swiss Federal Institute for Aquatic Science and Technology, Überlandstrasse 133, 8600 Dübendorf, Switzerland; [email protected] 3 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg 4 Leibniz Institute of Plant Biochemistry, Department of Stress and Developmental Biology, Weinberg 3, 06120 Halle, Germany; [email protected] 5 German Centre for Integrative Biodiversity Research (iDiv), Halle-Jena-Leipzig Deutscher Platz 5e, 04103 Leipzig, Germany 6 The International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France; [email protected] 7 Metabolomics Platform, IISPV, Department of Electronic Engineering, Universitat Rovira i Virgili, Avinguda Paisos Catalans 26, 43007 Tarragona, Spain 8 Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Monforte de Lemos 3-5, 28029 Madrid, Spain * Correspondence: [email protected] (F.J.); [email protected] (O.Y.); Tel.: +33-582-066-395 (F.J.); +34-977-776-617 (O.Y.) Received: 18 July 2018; Accepted: 7 September 2018; Published: 15 September 2018 Abstract: The use of mass spectrometry-based metabolomics to study human, plant and microbial biochemistry and their interactions with the environment largely depends on the ability to annotate metabolite structures by matching mass spectral features of the measured metabolites to curated spectra of reference standards.
    [Show full text]
  • Sensing Superfund Chemicals with Recombinant Systems
    Sensing Superfund Chemicals with Recombinant Systems Sapna K. Deo, S. Xu, D. Ghosh, X. Guan, A. Rothert, J. Feliciano, E. D’Angelo, Leonidas G. Bachas, and Sylvia Daunert Department of Chemistry and Department of Agricultural Sciences University of Kentucky Lexington, KY Molecular Recognition in Analytical Chemistry • Proteins • Cells • High Throughput Screening • Whole Cell-Based Sensing Systems Analyte No Analyte Signal Reporter protein No Expression of Reporter Protein Arsenic Poisoning • Applications • Agriculture • Treatment for diseases • Industrial uses • Long exposure to low doses of arsenic • Skin hyperpigmentation and cancer • Other cancers • Inhibition of cellular enzymes New Bangladesh Disaster: Wells that Pump Poison... New York Times November 10, 1998 Arsenic contamination in the USA U. S. Geological Survey, Fact Sheet FS 063-00, May 2000 Arsenite Resistance in E. coli O/P arsR arsD arsA arsB arsC Schematic Representation of the Antimonite/Arsenite Pump - - AsO2 SbO2 Cytoplasm ADP ATP AsO - ATP 3- 2 AsO4 ADP ArsA ArsA ArsC Periplasm Membrane ArsB - - AsO2 SbO2 Fluorescent Reporter Proteins in Array Detection Protein Excitation Emission λ max λ max GFP 395 (470) 509 EGFP 488 509 BFP 380 440 GFPuv 395 509 YFP 513 527 CFP 433 475 CobA 357 605 RFP 558 583 P H C 3 A Production of fluorescent A P porphyrinoid compounds H3C N HN oxidation NH N A A P A P H C 3 A A A P P P P NH HN H3C N HN UMT sirohydrochlorin NH HN SAM P A NH HN H3C A A A A A UMT P HN P P P P H3C N SAM urogen III Dihydrosirohydrochlorin (Precorrin-2) NH N A CH3
    [Show full text]
  • A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria
    A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria Chengyuan Song Shandong University Qilu Hospital Shaowei Sang Shandong University Qilu Hospital Yuan Liu ( [email protected] ) Shandong University Qilu Hospital https://orcid.org/0000-0003-4991-552X Research Keywords: acute hepatic porphyria, urinary urobilinogen, serum total bilirubin Posted Date: June 14th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-587707/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Background: Due to its variable symptoms and nonspecic laboratory test results during routine examinations, acute hepatic porphyria (AHP) has always been a diagnostic dilemma for physicians. Misdiagnoses, missed diagnoses, and inappropriate treatments are very common. Correct diagnosis mainly depends on the detection of a high urinary porphobilinogen (PBG) level, which is not a routine test performed in the clinic and highly relies on the physician’s awareness of AHP. Therefore, identifying a more convenient indicator for use during routine examinations is required to improve the diagnosis of AHP. Results: In the present study, we retrospectively analyzed laboratory examinations in 12 AHP patients and 100 patients with abdominal pain of other causes as the control groups between 2015 and 2021. Compared with the control groups, AHP patients showed a signicantly higher urinary urobilinogen level during the urinalysis (P < 0.05). However, we showed that the higher urobilinogen level was caused by a false- positive result due to a higher level of urine PBG in the AHP patients. Hence, we used serum total bilirubin, an upstream substance of urinary urobilinogen synthesis, for calibration.
    [Show full text]
  • Significance of Heme and Heme Degradation in the Pathogenesis Of
    International Journal of Molecular Sciences Review Significance of Heme and Heme Degradation in the Pathogenesis of Acute Lung and Inflammatory Disorders Stefan W. Ryter Proterris, Inc., Boston, MA 02118, USA; [email protected] Abstract: The heme molecule serves as an essential prosthetic group for oxygen transport and storage proteins, as well for cellular metabolic enzyme activities, including those involved in mitochondrial respiration, xenobiotic metabolism, and antioxidant responses. Dysfunction in both heme synthesis and degradation pathways can promote human disease. Heme is a pro-oxidant via iron catalysis that can induce cytotoxicity and injury to the vascular endothelium. Additionally, heme can modulate inflammatory and immune system functions. Thus, the synthesis, utilization and turnover of heme are by necessity tightly regulated. The microsomal heme oxygenase (HO) system degrades heme to carbon monoxide (CO), iron, and biliverdin-IXα, that latter which is converted to bilirubin-IXα by biliverdin reductase. Heme degradation by heme oxygenase-1 (HO-1) is linked to cytoprotection via heme removal, as well as by activity-dependent end-product generation (i.e., bile pigments and CO), and other potential mechanisms. Therapeutic strategies targeting the heme/HO-1 pathway, including therapeutic modulation of heme levels, elevation (or inhibition) of HO-1 protein and activity, and application of CO donor compounds or gas show potential in inflammatory conditions including sepsis and pulmonary diseases. Keywords: acute lung injury; carbon monoxide; heme; heme oxygenase; inflammation; lung dis- ease; sepsis Citation: Ryter, S.W. Significance of Heme and Heme Degradation in the Pathogenesis of Acute Lung and Inflammatory Disorders. Int. J. Mol. 1. Introduction Sci.
    [Show full text]
  • Vitamin B, and B,-Proteins Edited by Bernhard Krautler, Duilio Arigoni and Bernard T
    Vitamin B, and B,-Proteins Edited by Bernhard Krautler, Duilio Arigoni and Bernard T. Golding Lectures presented at the 4th European Symposium on Vitamin B,, and B,,-Proteins @ W I LEY-VCH Weinheim - Chichester - New York - Toronto. Brisbane - Singapore This Page Intentionally Left Blank Vitamin B, and BIZ-Proteins Edited by B. Krautler, D. Arigoni and B.T. Golding 633 WILEY-VCH This Page Intentionally Left Blank Vitamin B, and B,-Proteins Edited by Bernhard Krautler, Duilio Arigoni and Bernard T. Golding Lectures presented at the 4th European Symposium on Vitamin B,, and B,,-Proteins @ W I LEY-VCH Weinheim - Chichester - New York - Toronto. Brisbane - Singapore Prof. Dr. B. Krautler Prof. Dr. D. Arigoni Prof. Dr. B.T. Golding Leopold-Franzens-Universitat ETH-Zurich Department of Chemistry Innsbruck Laboratoriuin fur University of Newcastle Institut fur Organische Chemie Organische Chemie NE 17 RU Newcastle Iiinrain 52a Universitatsstrasse 16 upon Thyne A-6020 Innsbruck CH-8092 Zurich This book was carefully produced. Nevertheless, authors, editor and publisher do not warrant the in- formation contained theirein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. L I The cover picture shows a cartoon of B,,-dependent methionine synthase (see contribution by Drennan et al. in this book). The picture was kindly provided by Martin Tollinger, University of Innsbruck. Library of Congress Card No.: applied for British Library Cataloguing-in-Publication Data: A catalogue record for this book is available from the British Library Die Deutsche Bibliothek - CIP-Einheitsaufnahme Vitamin B,, and B,,-proteins :lectures presented at the 4th European Symposium on Vitamin B,, and B,,-Proteins / ed.
    [Show full text]
  • Concerning the Biosynthesis of Sirohaem in Bacillus Mesaterium the Relationship with Cohalamin Metabolism
    Concerning the Biosynthesis of Sirohaem in Bacillus mesaterium The Relationship with Cohalamin Metabolism Presented by Mr. Richard Beck For the award of Doctorate (Ph.D.) in Biochemistry at the University of London (University College London). Department of Molecular Genetics, Institute of Ophthalmology, University College London, Bath Street, London EClV 9EL. United Kingdom. March 1997 ProQuest Number: 10044378 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10044378 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Concerning the Biosynthesis of Sirohaem in Bacillus megaterium: The Relationship with Cobalamin Metabolism Sirohaem and vitamin B 12 (cyanocobalamin) share a significant part of their biosynthetic pathways, the last common intermediate being precorrin -2 (dihydrosirohydrochlorin). Dehydrogenation of precorrin-2 leads to sirohaem formation, whereas méthylation at C-20 directs production of vitamin B 12. A novel enzyme has been identified which may play a crucial role in regulating sirohaem and cobalamin biosynthesis at the precorrin-2 branch-point. In vivo, the CbiX protein from Bacillus megaterium has been shown to catalyse the final two steps of sirohaem synthesis, namely dehydrogenation and ferrochelation.
    [Show full text]
  • Acute Intermittent Porphyria Antonio Dajer, MD; Louis Cooper, MD
    CASE REPORT Acute Intermittent Porphyria Antonio Dajer, MD; Louis Cooper, MD A 34-year-old pregnant woman presented for evaluation of severe, persistent abdominal pain. Case A 34-year-old woman presented to the ED with severe, persistent abdomi- nal pain that had begun 18 days earlier. She was 7 weeks pregnant and had been seen in the same ED the day before. During that visit, ultra- sound had shown a single pregnancy of doubtful viability. Abdominal magnetic resonance imaging was normal. She was given multiple doses of hydromorphone. The discharge diagnosis was “missed abortion.” Since the onset of her pain, she had been hospitalized twice elsewhere, with no clear diagnosis to explain her pain. Treatment consisted of repeat doses of hydromorphone. During the second hospitalization, a sodium level of 109 mEq/L had been corrected with hypertonic saline, and a urinary tract infection (UTI) had been treated with cephalexin. Our patient had never experienced similar abdomi- nal pain. Her medical history included depression and asthma. Her family history was notable for an aunt who had died of lung cancer. On this ED visit, the patient’s vital signs were nor- mal. On examination, she was moaning in pain and clutching her abdomen. The abdomen was tender in both lower quadrants, with guarding but no re- bound. Her sodium level was 125 mEq/L; the day before it had been 132 mEq/L. Urine dipstick testing showed 2+ glucose and 2+ bilirubin; both had been within normal range (negative) the day before. An abdominal/pelvic computed tomography scan with intravenous (IV) and oral contrast did not reveal any potential cause of the patient’s pain.
    [Show full text]
  • HMBS Gene Hydroxymethylbilane Synthase
    HMBS gene hydroxymethylbilane synthase Normal Function The HMBS gene provides instructions for making an enzyme known as hydroxymethylbilane synthase. This enzyme is involved in the production of a molecule called heme. Heme is vital for all of the body's organs, although it is most abundant in the blood, bone marrow, and liver. Heme is an essential component of iron-containing proteins called hemoproteins, including hemoglobin (the protein that carries oxygen in the blood). The production of heme is a multi-step process that requires eight different enzymes. Hydroxymethylbilane synthase is responsible for the third step in this process, which combines four molecules of porphobilinogen (the product of the second step) to form a compound called hydroxymethylbilane. In subsequent steps, five other enzymes produce and modify compounds that ultimately lead to heme. Health Conditions Related to Genetic Changes Porphyria More than 300 mutations in the HMBS gene have been identified in people with a form of porphyria known as acute intermittent porphyria. Some of these mutations change single protein building blocks (amino acids) in hydroxymethylbilane synthase. Other mutations add or delete genetic material within the HMBS gene, which alters the structure and function of the enzyme. Mutations in the HMBS gene reduce the activity of hydroxymethylbilane synthase, allowing compounds called porphyrins to build up in the liver and other organs. These compounds are formed during the normal process of heme production, but reduced activity of hydroxymethylbilane synthase allows them to accumulate to toxic levels. This buildup, in combination with nongenetic factors such as certain drugs, alcohol, smoking, and dieting, leads to attacks of severe abdominal pain and other symptoms in people with acute intermittent porphyria.
    [Show full text]
  • Porphyrins and Heme in Microorganisms
    ! "#$ #%## & ' () * ( +,-% . ( / % / 0 1 2 ( % 3 4 % 4 ( / % 1 / %3 4 / 56( / / 78# (/ / 2 % / %3 ( / / / % / / // % / "$ %3 2 / 1 % 9 / / / / %3 / 8":/ / / % 4 ( % / 7#8 ;"%$!< " / 4 %- " 8;%,!< / =8# %3 / % > / / 78# 56 % / ( / % 9/ ( / / % > ( / % ( 2 ( % "#; ?<< %% < @ A ? ? ?? 7 7#8 >-B ;$ ;; ;#; $ >-B ;$ ;; ;#$#7 (#, PORPHYRINS AND HEME IN MICROORGANISMS Jonas Fyrestam Porphyrins and heme in microorganisms Porphyrin content and its relation to phototherapy and antimicrobial treatments in vivo and in vitro Jonas Fyrestam ©Jonas Fyrestam, Stockholm University 2018 ISBN print 978-91-7797-079-8 ISBN PDF 978-91-7797-080-4 Printed in Sweden by Universitetsservice US-AB, Stockholm 2017 Distributor:
    [Show full text]
  • Kent Academic Repository Full Text Document (Pdf)
    Kent Academic Repository Full text document (pdf) Citation for published version Dailey, Harry A. and Dailey, Tamara A. and Gerdes, Svetlana and Jahn, Dieter and Jahn, Martina and O'Brian, Mark R. and Warren, Martin J. (2017) Prokaryotic Heme Biosynthesis: Multiple Pathways to a Common Essential Product. Review of: Prokaryotic Heme Biosynthesis: Multiple Pathways to a Common Essential Product by UNSPECIFIED. Microbiology and Molecular DOI https://doi.org/10.1128/MMBR.00048-16 Link to record in KAR http://kar.kent.ac.uk/60615/ Document Version Publisher pdf Copyright & reuse Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder. Versions of research The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record. Enquiries For any further enquiries regarding the licence status of this document, please contact: [email protected] If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html REVIEW crossm Prokaryotic Heme Biosynthesis: Multiple Pathways to a Common Essential Product Downloaded from Harry A. Dailey,a Tamara A. Dailey,a Svetlana Gerdes,b Dieter Jahn,c Martina Jahn,d Mark R.
    [Show full text]